Management of cancer-associated disseminated intravascular coagulation: Guidance from the SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 671-675

  Thachil, J ^a   Falanga, A ^b   Levi, M ^c   Liebman, H ^d   Di Nisio, M ^e,f  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CHIETI   (Italy)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; D DIMER; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; PLASMIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID;

ARTICLE; CANCER ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION; CANCER PATIENT; CONSENSUS; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; LEUKOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; PROTHROMBIN TIME; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VENA CAVA FILTER; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG EFFECTS; NEOPLASM; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD TRANSFUSION; CONSENSUS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME; VENA CAVA FILTERS;

EID: 84926134907     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12838     Document Type: Article

References (22)

1. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009; 22: 129-36.
2. Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY; Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013; 11: 1760-5.
3. Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta 2014; 436C: 130-4.
4. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-7.
5. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-82.
6. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24-33.
7. Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012; 87: 596-603.
8. Levi M, Meijers JC. DIC: which laboratory tests are most useful. Blood Rev 2011; 25: 33-7.
9. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-A single center experience in 34 patients. Thromb Res 2005; 116: 109-14.
10. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle CE, Levi M, Toh CH, The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-7.
11. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007; 82: 864-73.
12. Falanga A, Iacoviello L, Evangelista V, Belotti D, Consonni R, D'Orazio A, Robba L, Donati MB, Barbui T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86: 1072-81.
13. Falanga A, Rickles FR. Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2007; 2007: 165-71.
14. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009; 113: 1875-91.
15. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014; 12: 1010-9.
16. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
17. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22: 153-63.
18. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147: 77-82.
19. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-7.
20. De la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111: 3395-402.
21. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010; 125: S51-4.
22. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-800.